This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07808060 |
|---|---|
| Status | Not yet recruiting |
| Phase | Phase 1 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 34 participants |
| Design | Interventional, Na, Single Group, Masking: None |
| Conditions | Obesity; Overweight |
| Interventions | Eloralintide; Combined oral contraceptive |
| Start | Sep 2026 |
| Primary completion | Jun 2027 |
| Study completion | Jun 2027 |
| Results posted | Not yet |
| Registry last updated | Sep 8, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study is to evaluate how eloralintide (LY3841136) effects the way the body processes oral contraceptive in female participants with obesity or overweight. For each participant, the study will last about 8 months and will include 3 stays in the Clinical Research Unit (CRU), each lasting between 6 - 8 nights.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of Ethinyl Estradiol and Levonorgestrel | Baseline through Day 128 |
| PK: Maximum Concentration (Cmax) of Ethinyl Estradiol and Levonorgestrel | Baseline through Day 128 |
| PK: Time to Maximum Concentration (Tmax) of Ethinyl Estradiol and Levonorgestrel | Baseline through Day 128 |
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
